据《彭博通讯社》引述知情人士指，信达生物(01801.HK) 在与一家顾问机构合作，评估全球制药公司对其自研首创PD-1/IL-2 Alpha-bias双特异性抗体融合蛋白产品“IBI363”的兴趣，预期通过向其他药厂授权该产品可推进研发及商业化进程。若达成授权协议，预期信达生物可获得前期付款及里程碑款项。消息指审议仍处于初步阶段。
信达生物早前指，正在中国、美国、澳洲开展临床研究探索IBI363在针对各种恶性肿瘤的有效性和安全性，目前IBI363已开出首个关键注册临床研究，用于治疗未经免疫治疗的粘膜型和肢端型黑色素瘤，另外亦已获美国FDA两项快速通道资格认定，分别用于治疗鳞状非小细胞肺癌和黑色素瘤。(gc/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-10 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.